Market Overview

UPDATE: ISI Group Raises PT to $27 on Hologic Following Guidance Raise

Related HOLX
17 Stocks Which Rallied Three Days On Increasing Volume
Hologic Investors Cheer As Barclays Upgrades To Overweight: 'Stronger For Longer' On Breast Health
Best Near-Term Price Gains Ahead For: Medical Equipment And Supplies Stocks (Seeking Alpha)

ISI Group maintained Hologic (NASDAQ: HOLX) with a Strong Buy rating and raised the price target from $25.50 to $27.00.

ISI Group commented, "Going forward, we expect increased adoption of 3D Tomo (as presaged by the continued sequential backlog increase) and Panther (Diagnostics) to drive growth upside. In the NT, receipt of a potential CMS reimbursement code for 3D Tomo will be a significant catalyst. Given our thesis for a new product cycle accelerating growth, we are reiterating our Strong Buy rating of HOLX shares and raising our price target from $25.50 to $27.00."

Hologic closed at $23.25 on Monday.

Latest Ratings for HOLX

Sep 2016BarclaysUpgradesEqual-WeightOverweight
Jul 2016Morgan StanleyMaintainsEqual-Weight
Jul 2016JefferiesMaintainsBuy

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Analyst Ratings


Related Articles (HOLX)

View Comments and Join the Discussion!